Medicine
Adempas 1.5 mg tablet
Adempas 1.5 mg tablet is a prescription medicine containing Riociguat for oral use, marketed by Bayer HealthCare Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions are permitted from 15°C to 30°C (59°F to 86°F).
Key facts
- Active ingredient (INN)
- Riociguat
- Brand
- Adempas
- Strength
- 1.5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 90 tablets, 2 blister pack, 9 tablets
- Marketing authorisation holder
- Bayer HealthCare Pharmaceuticals
- Manufacturer
- Bayer HealthCare Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions are permitted from 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C02KX05 Riociguat
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 October 2013
- Identifiers
- RxCUI 1439821, 1439823, 1439831 +7DailyMed set ID 7b57509a-3d5d-41d4-8fed-1471e26372a3NDC 50419-252Application NDA204819
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 90 tablet, film coated in 1 bottle | 50419-252-01 | Bayer HealthCare Pharmaceuticals | 8 December 2013 |
| 2 blister pack in 1 package / 21 tablet, film coated in 1 blister pack | 50419-252-03 | Bayer HealthCare Pharmaceuticals | 8 October 2013 |
| 9 tablet, film coated in 1 bottle | 50419-252-91 | Bayer HealthCare Pharmaceuticals | 18 September 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Riociguat 1.5 mg tablet.
Other strengths and forms of Riociguat
Clinical summary
Riociguat is a soluble guanylate cyclase stimulator indicated for the treatment of adults with persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. MedsAcross supplies Riociguat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RiociguatFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Adempas prescribing information (Bayer HealthCare Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Adempas: European public assessment report (EPAR) · European Medicines Agency
Need Adempas 1.5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.